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Abstract 
Zoonoses, often better defined with the term anthropozoonoses, are diseases that can be transmitted 
to humans either by direct contact with animals or through arthropod vector intervention. Microbial 
interaction between humans and animals constitutes an important public health challenge, 
particularly in the Mediterranean basin. The main reasons this challenge is still relevant today 
include the phenomenon of migration, of both humans and animals, and climate change, which 
tend to alter the geographical distribution of zoonosis or the zoonotic agent, as well as the 
distribution range of potential vectors. The Mediterranean area seems to be affected by plentiful 
and widely distributed zoonoses, the main diseases being rickettsiosis, leishmaniasis, brucellosis, 
hydatid disease and viral zoonoses. The aim of this study is to revisit the prevalence and main 
clinical features of anthropozoonoses observed at the Department of Sciences for Health Promotion 
and Mother & Child Care, University of Palermo, Sicily, Southern Italy.  
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Introduction 
The Mediterranean area seems to be affected by 
plentiful and widely distributed zoonoses. The 
reasons for this concentration are to be referred to 
the great biodiversity and the close co-existence 
between people and animals 1-3. Zoonoses, an 
all encompassing term, better often defined with 
the term “anthropozoonoses” (diseases transmitted 
to man from other vertebrates), defines a large 
group of infectious diseases that still represent a 
public health challenge due to the complex 
microbial interaction between humans and 
animals 4-13. Many zoonotic diseases have 
disappeared or been eradicated: historical 
examples are the plague (absent for more than 
three centuries), canine rabies (or urban, last 
reported case in 1974), sylvatic rabies and 
American myiasis (Cochliomyia hominivorax, the 
killer fly, introduced in the 1990s and promptly 
eradicated thanks to the release into the 
environment of sterile males). Other zoonotic 
diseases are still present in the Mediterranean 
basin: rickettsiosis, leishmaniasis and brucellosis 
are well-known diseases, while others are 
emerging and rare 1-3,14-19.  
Furthermore, the multidimensional 
phenomenon of migration, climate change and the 
increase in national and international transport are 
changing the geographical distribution of the 
zoonosis or the zoonotic agent, as well as the 
distribution range of potential vectors [20-24]. 
Rickettsiosis 
Rickettsiosis is a globally widespread zoonosis 
caused by gram-negative bacteria belonging to the 
genus Rickettsia and Orientia, which are 
transmitted by arthropod vectors (lice, fleas, ticks 
and mites). In Europe only the species belonging 
to the genus Rickettsia are responsible for 
Rickettsiosis, and typically fall into two general 
groups: the spotted fever group and the typhus 
group. 
The endemic typhus (murine typhus) caused by 
Rickettsia typhi and transmitted by the rat flea (X. 
cheopis) is common in Mediterranean countries 
(Spain, Croatia, Greece, Cyprus). Rickettsia felis 
is found in the cat flea (C. felis) with high vector 
prevalence in Europe [25].  
However in Europe the predominant 
rickettsioses belong to the spotted fever group. 
Mediterranean spotted fever (MSF), one of the 
oldest-recognized vector-borne infectious 
diseases, is an endemic zoonosis in the 
Mediterranean basin. MSF is caused by Rickettsia 
conorii subsp. conorii and it is endemic in 
southern Europe with sporadic documented cases 
in some regions of northern and central Europe; 
Rhipicephalus sanguineus is the principal vector 
and reservoir. The clinical presentation includes 
fever, maculopapular rash, and the presence of a 
tache noir on the tick bite site. Most of the time 
the clinical course is positive, with a mortality rate 
of 3-7% in hospitalized patients. Most cases are 
reported in the summer months, when ticks are 
very active. In the southern European region the 
higher temperatures permit the persistence and 
abundance of ticks and for this reason cases can 
be reported during the spring. In Italy, each year 
about 300 MSF cases are reported, of which more 
than half are in Sicily [26,27]. Rickettsia conorii 
subsp. conorii has long been considered the only 
pathogen rickettsia in Europe. However, in recent 
decades the use of molecular biology techniques 
allowed the identification of new rickettsia species 
and subspecies as new emerging pathogens 
responsible for new clinical diseases different 
from the classical form of FBM: Rickettsia 
conorii subsp. israelensis, Rickettsia conorii 
subsp. caspia, Rickettsia conorii subsp. indica, 
Rickettsia slovaca, Rickettsia raoultii, Rickettsia 
monacensis, Rickettsia massiliae, Rickettsia 
aeschlimannii, Rickettsia helvetica, Rickettsia 
sibirica subsp.sibirica and Rickettsia sibirica 
subsp mongolitimonae. In 1996 and 1997 in 
France the first case of human infection with 
Rickettsia slovaca and Rickettsia sibirica 
mongolitimonae was described; Rickettsia 
massiliae was identified for the first time in 
Marseille and was recognized as a disease agent in 
Sicily in 2006 [28]. In 2003 in Sicily, Rickettsia 
conorii subsp.israelensis was identified, agent of 
the Israeli spotted fever (ISF), documented in Italy 
(Sicily and Sardinia) and in other Mediterranean
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areas (e.g. Portugal). The distribution of ISF has 
proved to be wider than previously thought, and it 
is now possible to assert that many of the MSF 
severe clinical pictures described in the literature 
should be attributed to R. rickettsii subsp. 
Israelensis [29]. Lastly, TIBOLA / DEBONEL / 
SENLAT, acronyms for respectively, 'Tick-Borne 
Lymphadenopathy' / 'Dermacentor-Borne 
Necrosis Erythema Lymphadenopathy' / 'Scalp 
ESCHAR and Neck Lymphadenopathy After Tick 
Bite', are caused by Rickettsia slovaca, 
Candidatus Rickettsia and Rickettsia raoultii. The 
main vector in these cases is Dermacentor 
marginatus and the major symptoms are necrotic 
eschar on the scalp associated with painful 
cervical lymphadenopathy [28]. 
Although MSF is mostly a self-limited disease 
characterized by fever, skin rash, and a dark 
eschar at the site of the tick bite called a 'tache 
noire', serious complications have been described, 
mainly in adult patients [30-35]. 
Tetracyclines are considered standard treatment 
for MSF, even though they can cause significant 
adverse effects like staining of the teeth and bone 
toxicity, especially in children. For this reason, 
macrolides have emerged as a potential alternative 
therapy in children [36-38]. 
Leishmaniasis 
Leishmaniases are a group of vector-borne 
parasitic diseases caused by protozoa belonging to 
the genus Leishmania. Generally, Leishmania 
infection is transmitted to humans and to other 
mammals by the bite of an infected sand fly 
vector. Rarely, the infection can be transmitted 
through blood transfusions, by needle sharing, or 
from mother to child during pregnancy. The 
World Health Organization (WHO) has stated that 
leishmaniasis is one of the most neglected 
diseases, with 350 million people considered at 
risk of contracting the disease, a burden of about 
12 million people currently infected in 98 
countries, and two million new cases estimated to 
occur annually. Among these, visceral 
leishmaniasis (VL) accounts for about 500 000 
cases each year. The clinical spectrum includes 
cutaneous, mucocutaneous and visceral forms. 
Asymptomatic infections have also been 
demonstrated, but their role has yet to be clarified. 
Parasite, vector and host, and their complex 
interplay, determine the different clinical forms of 
VL [40]. It has been estimated that in endemic 
areas the proportion of asymptomatic infections is 
5–10 times greater than the number of clinically 
apparent VL cases in immunocompetent hosts. 
Cryptic infection can be detected in people 
without a previous history of clinical VL by 
serological evidence of anti-Leishmania 
antibodies, by detection of parasite DNA in blood 
samples, or by a positive reaction to the 
leishmanin skin test (LST) [41,42]. Asymptomatic 
infection has also been demonstrated in HIV-
infected patients. Also in this population, the 
percentage of asymptomatic infection could be 
higher than symptomatic cases. Leishmania 
parasitemia was found to be significantly higher 
in patients with higher viral loads. A high 
parasitemic burden could possibly be related to a 
higher risk of developing symptomatic disease, 
due to the reciprocal effects that enhance the 
multiplication of both pathogens [42-44]. 
In the immunocompetent host, VL is caused by 
a primary infection with Leishmania parasites 
transmitted by the bite of a phlebotomine sand fly. 
VL is the result of a chronic infection; the 
incubation period ranges from 10 days to 1 year. 
Clinical features of typical forms are fever, weight 
loss, hepatosplenomegaly, and pancytopenia. 
Fever can be intermittent in the first period and 
successively continuous. Non-tender 
splenomegaly and hepatomegaly are caused by 
infection of the reticuloendothelial system. 
Pancytopenia caused by parasites invading the 
bone marrow is responsible for pallor due to 
anaemia, and can subsequently cause 
haemorrhages due to thrombocytopenia and 
concurrent infections due to leukopenia. Anorexia 
and weight loss can lead to wasting syndrome in 
misdiagnosed cases [44-47]. PCR on peripheral 
blood allows a rapid and non-invasive 
parasitologic diagnosis of VL [48,49]. 
Leishmaniasis has been reported among 
transplant recipients, HIV patients and among 
other immunosuppressed patients 41,50,51.
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Anti-leishmanial treatment is based on the 
systemic administration of one or a combination 
of effective drugs. Alongside pentavalent 
antimonials, which have been the standard first-
line medicines for many decades, new anti-
leishmanial drugs such as lipid formulations of 
amphotericin B, miltefosine, and paromomycin 
are currently used for the treatment of VL. Lipid 
formulations of amphotericin B, and in particular 
liposomal amphotericin B, are considered to be 
the drugs of choice for the treatment of VL 
[52,53]. 
Case reports and small series have anecdotally 
reported the successful use of liposomal 
amphotericin B or pentavalent antimony in VL 
complicated by secondary hemophagocytic 
lymphohistiocytosis [49]. 
Conditions of depression of the immune 
system, such as HIV infection or 
immunosuppressive treatments in transplant 
recipients and in patients with autoimmune 
diseases impair the capability of the immune 
response to resolve the infection and allow the 
reactivation of the disease from sites of latency of 
the parasite. Reactivation of chronic infection can 
occur long after primary contact with the parasite 
[52-55]. Appropriate screening for leishmaniasis 
before beginning immunosuppressive treatments 
could be useful for calling to attention the 
potential risk for VL in the immunocompromised 
host. The LST (Montenegro test), an intradermal 
injection of a suspension of killed promastigotes, 
measures delayed hypersensitivity reactions and 
appears to be valuable for detecting asymptomatic 
Leishmania infections 56. 
Brucellosis 
Brucellosis is a zoonotic infection in domestic 
and wild animals that is caused by organisms of 
the Brucella genus. Humans become infected by 
ingesting unpasteurized dairy products, being in 
direct contact with infected animals, or inhaling 
infectious aerosols. Brucellosis is one of the 
world’s most widespread zoonoses. The 
distribution of this disease is worldwide, and areas 
of high endemicity include the Mediterranean, the 
Middle East, Latin America and Asia 7,57. 
Domestic animals harbouring Brucella spp. are 
raised where adequate control measures are 
lacking and where the population has the custom 
of ingesting unpasteurized milk or its products. In 
Sicily, the largest Italian island, brucellosis is 
highly endemic and has shown a marked 
resurgence in the last few years (14 cases per 
100,000). 
However, fewer than 200 cases are reported per 
year (0.04 cases per 100,000 population) in the 
United States. 
Brucella spp. are intracellular pathogens that 
can survive and multiply within mononuclear 
phagocytes (monocytes and macrophages) of the 
reticuloendothelial system (RES). Localization 
within organs of RES may explain some of the 
clinical manifestations of systemic brucellosis, 
such as hepatosplenomegaly and the propensity 
for involvement of the skeletal system. Lack of 
feasible microbiological methodologies 58 or 
effective treatment may result in serious and 
sometimes life-threatening complications such as 
spondylitis, endocarditis and encephalitis [59-62].  
Patients frequently experience relapse, even 
with treatment, and the disease often becomes 
chronic (i.e., a clinical manifestation of >6 months 
duration).  
Tolomeo et al. have shown that a high level of 
apoptosis resistance among monocytes and 
lymphocytes during and after therapy may 
therefore represent an index of chronic illness, 
suggesting to the clinician, in some cases, that a 
change in therapy is required 63.  
The treatment of choice for acute brucellosis is 
considered a 6-week regimen of tetracycline 
administered orally in combination with 
streptomycin (1 g/day intramuscularly for 2-3 
weeks). Although other antibiotics have been 
used, no substantial improvement in relapse rates 
has been reported in association with any new 
treatment regimen in the past 45 years [4]. In 
1986, the World Health Organization (WHO) 
recommended therapy with the combination of 
doxycycline (200 mg/day) plus rifampin (600-900 
mg/day) both administered once daily by mouth 
for 6 weeks [64,65]. 
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Cascio et al. 63 showed that the combination 
of intravenous rifampin plus oral minocycline 
administered for 3 weeks obtained the lowest 
relapse rate (1.7%). This combination therapy, 
like those reported by WHO (i.e. doxycycline plus 
rifampin) versus streptomycin plus doxycycline, 
showed a relapse rate of 16% and 5.3%, 
respectively 66. 
Experience with different treatments in 
childhood brucellosis is sparse and generally 
tetracyclines are not used in children ≤8 years of 
age [67,68]. Cascio et al. have published a study 
suggesting that minocycline could be used (for a 
maximum of 3 weeks) to treat infections in 
pediatric patients when indicated 69. 
Other rare zoonotic diseases 
Erysipelothrix rhusiopathiae is a common 
commensal or pathogen of many vertebrate and 
invertebrate species. Pigs are a major reservoir. 
Human disease is mainly an occupationally 
acquired zoonosis. The portal of entry is typically 
a puncture wound or abrasion on the hand; 
however, it can also be acquired from eating 
contaminated food [70]. 
The global burden of leptospirosis remains 
enormous and new aspects of the disease are 
constantly being recognized [71]. 
Of note, animal rotaviruses, astrovirus, and 
picobirnavirus might be able to cross species 
barriers, and lack of systematic surveillance of 
rotavirus infection in small animals hinders the 
ability to establish firm epidemiological 
connections [14,71-75]. 
Echinococcosis and other helminthic diseases 
are endemic in Southern Italy [8,9,18]. 
Over the last ten years, studies have confirmed 
that besides mammals, birds too are responsible 
for arthropod human infestation. Migratory wild 
birds play an important role in the ecology and 
circulation of potential zoonotic pathogens in 
Sicily 76,77. 
Castelli et al. showed how the bite of an avian 
arthropod, such as Ornithonyssus species of bird 
parasite, could be responsible for dermatitis in a 
Sicilian patient 77. 
In conclusion, Southern Italy and Sicily in 
particular could be affected by emerging diseases 
caused by the passage of animals carrying 
arthropods other than well-known ones such as 
ticks, and this might be the consequence of 
climate tropicalization, which carries 
unpredictable epidemiological and ecological 
implications. 
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